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Abstract
Platelet-derived growth factor (PDGF) exerts multiple cellular effects that stimulate wound repair in multiple tissues.
However, a major obstacle for its successful clinical application is the delivery system, which ultimately controls the in vivo
release rate of PDGF. Polylactic-co-glycolic acid (PLGA) microspheres (MS) in nanofibrous scaffolds (NFS) have been shown
to control the release of rhPDGF-BB in vitro. In order to investigate the effects of rhPDGF-BB release from MS in NFS on gene
expression and enhancement of soft tissue engineering, rhPDGF-BB was incorporated into differing molecular weight (MW)
polymeric MS. By controlling the MW of the MS over a range of 6.5 KDa–64 KDa, release rates of PDGF can be regulated
over periods of weeks to months in vitro. The NFS-MS scaffolds were divided into multiple groups based on MS release
characteristics and PDGF concentration ranging from 2.5–25.0 mg and evaluated in vivo in a soft tissue wound repair model
in the dorsa of rats. At 3, 7, 14 and 21 days post-implantation, the scaffold implants were harvested followed by assessments
of cell penetration, vasculogenesis and tissue neogenesis. Gene expression profiles using cDNA microarrays were performed
on the PDGF-releasing NFS. The percentage of tissue invasion into MS-containing NFS at 7 days was higher in the PDGF
groups when compared to controls. Blood vessel number in the HMW groups containing either 2.5 or 25 mg PDGF was
increased above those of other groups at 7d (p,0.01). Results from cDNA array showed that PDGF strongly enhanced in
vivo gene expression of the CXC chemokine family members such as CXCL1, CXCL2 and CXCL5. Thus, sustained release of
rhPDGF-BB, controlled by slow-releasing MS associated with the NFS delivery system, enhanced cell migration and
angiogenesis in vivo, and may be related to an induced expression of chemokine-related genes. This approach offers a
technology to accurately control growth factor release to promote soft tissue engineering in vivo.
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Introduction
Growth factors are essential for cellular signaling for migration,
proliferation, differentiation, and maturation.[1] However, the
development of an effective delivery system that integrates
appropriate scaffolds and growth factors for specific tissue repair
and regeneration presents a clinical challenge. [2] Recently,
nanofibrous scaffolds with controlled-release growth factors have
shown significant potential for tissue engineering applications.[3]
Platelet derived growth factor (PDGF) is a multifunctional
growth factor family, composed of A, B, C, and D polypeptide
chains which can form homo- or heterodimeric molecules, [4]
which can then bind to two structurally related, intrinsic tyrosine
kinase receptors (PDGF-Ra and PDGF-Rb) to exert its biological
effects. [5] PDGF not only participates in embryonic development
of organs such as kidney, heart, and vasculature, [6] but also plays
a very important role in postnatal tissue repair, regeneration and
disease development. [7–9]
PDGF possesses biological functions on cellular chemotaxis,
mitogenesis, proliferation, extracellular matrix synthesis, anti-
apoptosis and vascularization. [6,10–14] As a potential therapeutic
agent, PDGF has been widely studied both preclinically and
clinically. It has been shown that when PDGF-BB is locally delivered
by peptide nanofibers, it not only prevented cardiomyocyte death
and maintained systolic function after myocardial infarction
preclinically; italsodecreased infarct sizeafterischemia/reperfusion.
[15,16] Furthermore, pre-administration of PDGF-AB decreases the
extent of myocardial injury in an aged rat myocardial infarction
model. [17] These results are in part because PDGF promotes
collagen synthesis, recruits mural cells through neovessels and
regulates maturation of the infarct vasculature. [18] PDGF is FDA-
approved for the treatment of neurotrophic diabetic ulcers[19] and
for promoting bone repair of periodontal osseous defects, [8,20]
indicating that PDGF has an important impact not only on soft
tissues, but also on osseous tissues.
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are biodegradable polymers with great potential for use in delivery of
polypeptides and proteins, because, in addition to their biocompat-
ibility, the release rate of polypeptides can be controlled by adjusting
the factor loading, polymer molecular weight, lactide/glycolide ratio
in the copolymer, and formulation methods.[21,22] Recently, our
group has developed a novel PLLA (poly-L-lactic acid) porous
scaffold with the characteristic of PLLA nanofibrous pore walls
(instead of the solid pore walls), which increases the scaffold porosity
to 98%, favoring diffusion of nutrients and oxygen.[23] In addition,
based on the finding that polymers with high molecular weight
(HMW) degrade more slowly than those with low molecular weight
(LMW),theinvivoreleaseofgrowthfactorembeddedinmicrospheres
is controlled by molecular weight,[22] which is different from the
traditional simple coating method in which the release rate of growth
factors depends on physico-chemical interactions between the
adsorbed growth factors and scaffold surfaces.
In order to study the feasibility of PLLA nanofibrous scaffold
(NFS)/microsphere (MS) constructs for tissue engineering and their
effects on PDGF biological functions on tissue neogenesis and
vascularization, PLLA NFS containing rhPDGF-BB encapsulated
in PLGA MS of different MW were implanted subcutaneously in
vivo, and the implant-tissue constructs were harvested and analyzed
by histology, histomorphometry, cDNAarray, and quantitative
real-time PCR.
Materials and Methods
Polymeric microsphere (MS) preparation
Poly(lactide-co-glycolide) microspheres with diameter in the
sub-micrometer to nanometer range were fabricated using an
established double emulsion technique.[23] Briefly, 100 mlo fa
0.3 mg/ml PDGF-BB solution (in 20 mM sodium acetate,
pH=6.3) was emulsified into 1 ml of 10% PLGA with MW
6.4 kD or 65 kD in dichloromethane (DCM) solution, using a
probe sonicator at 15 W (Virsonic 100, Cardiner, NY) for 10 s
over an ice bath to form the primary water-in-oil (w/o) emulsion.
The w/o emulsion was mixed with 20 ml of 1% PVA aqueous
solution under sonication to form a water-in-oil-in-water (w/o/w)
double emulsion. The emulsion was then magnetically stirred at
room temperature (RT) for at least 3 h to evaporate dichloro-
methane then centrifuged to collect solid microspheres. The
resultant microspheres containing PDGF-BB were washed twice
with distilled water, freeze-dried, and stored at 280uC until use.
Fabrication of poly(L-lactic acid) (PLLA) nanofibrous
scaffolds
PLLA macroporous nano-fibrous scaffolds were fabricated by a
combination of the phase separation and sugar-leaching tech-
niques. Briefly, 600 ml of 10% PLLA/THF solution was cast
under mild vacuum into an assembled sugar template by bound
sugar spheres approximately 250–425 mm in diameter. The
polymer/sugar composite was phase separated overnight at
220uC and then immersed for 2 days in cyclohexane to exchange
THF. Following lyophilization, the sugar spheres were leached out
in distilled water and highly porous scaffolds were formed. After
re-lyophilizing, the scaffolds were cut into circular disks with
dimensions of 7.2 mm in diameter and 2 mm in thickness. The
average weight of the porous scaffolds was 2.5–3.0 mg each.
Incorporation of PLGA microspheres into PLLA
PLGA microspheres containing PDGF-BB were incorporated
into PLLA nano-fibrous scaffolds using a post-seeding method.
Briefly, dry PLGA MS were suspended in hexane at a
concentration of 5 mg MS/ml. Eighty microliters of the
suspension were seeded onto each scaffold and the scaffold was
air-dried for 30 min to evaporate the solvent. This procedure was
repeated until one scaffold contained 2.5 or 25 mg rhPDGF-BB
(BioMimetic Therapeutics, Inc., Franklin, TN). This calculation
was based on a 77% encapsulation efficiency of PDGF-BB in the
microspheres, as previously described [23]. The scaffold was then
subjected to a mixed solvent of hexane/THF (volume ratio of 90/
10) to immobilize the microspheres on the scaffold which was then
vacuum-dried for 3 d to remove the solvent. The controls were
scaffolds seeded with microspheres without PDGF-BB.
PDGF scaffold implantation in vivo
All the animal experimental procedures were approved by the
University of Michigan Committee of Use and Care of Animals.
In order to investigate the effect of PDGF release rate on PDGF
biological function in vivo, nine groups of 3 animals each were
prepared to test in a rat wound healing model. [24] They were
grouped as follows:
Empty nanofibrous scaffold
Nanofibrous scaffold+65 kD microspheres without PDGF-BB
Nanofibrous scaffold+6.4 kD microspheres without PDGF-BB
Nanofibrous scaffold+2.5 mg PDGF-BB (simple coating)
Nanofibrous scaffold+25 mg PDGF-BB (simple coating)
Nanofibrous scaffold+6.4 kD microspheres containing 2.5 mg
PDGF-BB
Nanofibrous scaffold+6.4 kD microspheres containing 25 mg
PDGF-BB
Nanofibrous scaffold+65 kD microspheres containing 2.5 mg
PDGF-BB
Nanofibrous scaffold+65 kD microspheres containing 25 mg
PDGF-BB
Under isoflurane anesthesia, mid-sagittal incisions were made
on the dorsa of Sprague Dawley rats (200 g weight from Harlan,
Indianapolis, IN). Each scaffold implant construct was inserted
into a surgical pocket in triplicate for each assay (using 3 different
rats). The incisions were stapled closed. Assays included histologic
analysis (n=3 animals/group) and cDNArray/real time PCR
analysis (n=3 animals/group). Four blocks were placed in each
animal, and the implants were harvested at 3, 7, 14, and 21 days.
Histology, histomorphometry and
immunohistochemistry
The harvested pellets were fixed in 10% neutral buffered
formalin, embedded in paraffin, and longitudinally cut into 4- or
5-mm thick cross sections. Chosen sections were stained with
hematoxylin and eosin to evaluate the nature of tissue neogenesis.
Images of these specimens were captured using a Nikon Eclipse
50i microscope (Nikon, Inc., Melville, NY) fitted with a Nikon
Digital Sight DS U1 camera (Nikon, Inc., Melville, NY) for
analysis using Image Pro Plus
TM software (Media Cybernetics,
Silver Spring, MD). The entire area of the specimen and the area
of tissue penetrating into scaffolds were measured. The remaining
slides were used to perform Factor VIII-related antigen/von
Willebrand factor immunohistochemical staining with an anti-
human Factor VIII-related antigen/von Willebrand factor rabbit
polyclonal antibody (NeoMarkers, Fremont, CA) and a DakoCy-
tomation EnVision
+H System-HRP(AEC) kit (Dako North Amer-
ica, Carpinteria, CA). The area and number of positive-stained
blood vessels within the scaffolds were measured.
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After removal of the tissue-scaffold implants, pellets were directly
placed into liquid nitrogen, pulverized into fine particles, and
transferred into 15 ml centrifuge tubes (Becton Dickinson Labware,
Franklin Lakes, NJ). Total RNA extraction was performed using
TRIzol reagent (Invitrogen, Carlsbad, CA) according to manufac-
turer’s protocol. In brief, 2 mlTRIzol wasadded intoeachtube, and
the tubes were placed at RT for 20 min. After centrifugation at
3000 rpm for 15 min, the supernatants were transferred into new
tubes. Following protein denaturation by chloroform addition and
centrifugation, RNA was precipitated by isopropanol, washed with
75% Alcohol and dried. The RNA was then solublized and cleaned
using DNase I and the RNeasy Mini Kit (QIAGEN Inc, Valencia,
CA) according to provided protocols.
Affymetrix GeneChip Analysis
From histology, the groups of NFS carrying 25 mgP D G Fi nM S
had the most obvious tissue penetration and tissue neogenesis (Fig. 1
and 2). Thus, in order to screen the potential genes related to PDGF
function in vivo, those two groups were selected, and 5 mg RNA from
eachof3 specimens ineachgroupwaspooled togetherasthe sample
for Affymetrix GeneChip Analysis to screen for potential gene
candidates to be subsequently assessed by quantitative real-time
PCR. The group of empty NFS was used as a control.
Ten micrograms of total RNA was quantitatively amplified and
biotin-labeled according to the Affymetrix GeneChip Expression
Analysis Technical Manual. Briefly, RNA was converted to double-
stranded complementary DNA (cDNA) using a SuperScript II RT
kit (Invitrogen, Carlsbad, CA) with a T7-(T)24 primer (Proligo). The
cDNA was then used for in vitro t r a n s c r i p t i o ni nt h ep r e s e n c eo f
biotin-modified ribonucleotides (Enzo) to amplify single-stranded
RNA. The biotin-labeled RNA was fragmented and 10 mg
hybridized to a gene chip (Rat Genome 230 2.0 Array (Affymetrix,
Santa Clara, CA)) at 45uC for 16 h. Chips were washed and stained
with streptavidin R-phycoerythrin (Molecular Probes). After scan-
ning the chips, the data were analyzed using Affymetrix GeneChip
related software, Microarray Suite and Data Mining Tool.
Quantitative Real-Time PCR
In order to verify the cDNArray results, quantitative Real-time
PCR was performed using ABI Prism Sequence Detection System
7700 (Applied Biosystems, Foster City, CA). First, 1 mg total RNA
was used as a template to generate cDNA with an oligo d(T) primer
using the TaqMan Reverse Transcription Reagents kit (Applied
Biosystems, Foster City, CA). Thermal conditions were: 25uC,
10 min; 48uC, 30 min and 95uC, 5 min. For the real time PCR, a
30 mlPCRreactionwaspreparedwith1 mlcD NA(R Tp ro du ct )a nd
1.5 ml mixture of gene specific probe (FAM dye) and primers from
AppliedBiosystems.ThesequencesfortheprobesarelistedinTable1.
The PCR thermal conditions were: 50uC, 2 min; 95uC, 10 min
followed by 40 cycles of 95uC, 15 sec and 60uC, 1 min. The ABI
Prism Sequence Detection System 7700 and its operational software
are capableof determining the linearphase of PCR reaction.An18S
primer and probe was used as an endogenous control.
Statistical Analyses
The differences among groups for tissue penetration, tissue area,
blood vessel number and gene expressions in real time PCR were
statistically assessed by one-way analysis of variation (ANOVA) with
Tukey multiple comparison post hoc test using a statistical software
package Prism 4 (GraphPad Co. San Diego, CA). There was a
minimumof three samples per groupavailablefor analysis.The level
of significance was considered as p,0.05. For microarray assess-
Figure 1. PDGF-containing microspheres (MS) in nanofibrous
scaffolds (NFS) stimulates tissue invasion in vivo. Left panel at
low magnification (2X) shows the tissue completely penetrated the
entire NFS for the groups with PDGF encapsulated in PLGA
microspheres, while other groups show a portion of scaffold occupied
by ingrown tissue. In addition, the scaffolds were enlarged by the
penetrated tissues in the groups with high dose PDGF encapsulated in
PLGA microspheres. Right panel at high magnification (10X) demon-
strated that most of the cells in the penetrated tissues were fibroblast-
like cells and lymphocyte-like cells. On the scaffold pore surfaces
multiple macrophage-like cells were seen. Bars indicate 0.5 mm.
doi:10.1371/journal.pone.0001729.g001
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Samples were displayed using an arbitrary 10-fold change cut-off for
subsequent assessment for quantitative real time PCR analysis.
Results
Histology and Histomorphometry
At 3 days post-implantation, no significant tissue ingrowth into
the scaffolds was found in any of the groups (data not shown).
However, by 1 week, penetrating tissue occupied the entire scaffold
spaces in several groups containing PDGF encapsulated in MS,
while thetissuepenetration wasseen only in thesuperficial regions of
scaffolds in the groups with PDGF-coating only and the groups
devoid of PDGF (Fig. 1). In addition, there was more vascularization
and thicker connective tissue capsules surrounding scaffolds in the
groups with PDGF encapsulation by microspheres than without
PDGF containing MS. Not only did the NFS become larger in
volume than their original shape, but also the porous structure of
scaffolds appeared irregular and distorted, in contrast to the groups
without PDGF encapsulated by MS. These findings were more
noticeable in the groups of scaffolds with high dose PDGF MS than
with low dose PDGF microspheres (Fig. 1). At 2 and 3 weeks, tissue
invaded into the entire scaffold area for all groups (data not shown).
In parallel with the 1 week histological observations, the
histomorphometry measurement results of 1 week specimens in
Fig. 2 showed that the areas representing the specimen volume
were significantly greater in the groups of NFS containing PDGF
encapsulated in HMW MS and high dose PDGF encapsulated in
LMW microspheres than the other groups. With regard to the
tissue penetration percentage (penetration tissue area versus the
whole area), the tissue invasion in the groups containing PDGF
encapsulated by microspheres was greater than the groups with
PDGF and the group with 2.5 mg PDGF coating.
PDGF-BB MS in NFS Stimulates Neovascularization in vivo
In order to explore the in vivo biological functions of PDGF
delivered by microspheres in nanofibrous scaffolds on blood vessel
formation, the vascularization within scaffolds was investigated using
Factor VIII-related antigen/von Willebrand factor immunohisto-
chemical staining. Figure 3 indicates that at 7d, vascularization
forming inside scaffolds was greater in the groups of PDGF
encapsulated in HMW microspheres, which is in accordance with
the results of measurements of blood vessel number. There were
significantlymoreblood vesselsformedinthe groups which contained
NFS plus PDGF encapsulated in HMW microspheres (Fig 4).
However, at 3, 14, and 21d, blood vessel number in the scaffolds
displayed no significant difference among all groups (data not shown).
cDNA array screening for potential PDGF-inducible genes
In order to screen the potential gene expression changes
induced by PDGF, RNA was extracted from 7 d specimens and
used to perform cDNA array analysis. In order to target genes
Figure 2. Histomorphometric analysis results of PDGF-inducing
tissue penetration and neogenesis. A is percentage of tissue
penetration. The percentage of tissue penetration within the groups of
PDGF encapsulated in PLGA MS was statistically greater than that for
the other groups with the exception of the 25 mg PDGF coating group.
The percentage of tissue penetration in the 25 mg PDGF coating group
is significantly greater than for the NFS only group. B demonstrates the
areas for all groups. The areas in the groups for PDGF encapsulated in
PLGA MS are statistically greater than those in the groups for NFS only,
NFS containing empty, slow, and fast release PLGA microspheres, and
2.5 mg PDGF coating group. The groups with 2.5 mg PDGF encapsulated
in slow release PLGA microspheres and 25 mg PDGF encapsulated in
slow and fast release PLGA microspheres have larger areas than the
groups with 25 mg PDGF coating and 2.5 mg PDGF encapsulated in fast
release PLGA microspheres. The largest area was found in the group of
25 mg PDGF encapsulated in fast release PLGA microspheres. * indicates
p,0.01, ** indicates p,0.05
doi:10.1371/journal.pone.0001729.g002
Table 1. Real-time PCR probe sequences
Genes Assay ID Probe Sequence Locus
CXCL1 Rn00578225_m1 TTGTCCAAAAGATGCTAAAGGGTGT NM_030845
CXCL2 Rn00586403_m1 TCCAAAAGATACTGAACAAAGGCAA NM_053647
CXCL5 Rn00573587_g1 GAGCTCAAGCTGCTCCTTTCTCGGC NM_022214
CCL21bRn01764651_g1 GCTCCAAAGGCTGCAAGGGGACTGA NM_001008513
doi:10.1371/journal.pone.0001729.t001
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expression was used as the cut-off and results are displayed in
Table 2. The cDNA array profiles demonstrate that PDGF
primarily up-regulated the expression of three groups of potential
genes. First, chemokine family genes such as CXCL1, 2, 5, and
CCL 21b were up-regulated from 48.4-fold to 148.9-fold.
However, CCL22 was down-regulated by 15.6-fold. Secondly,
muscle-related or cell-backbone-related genes such as a-actin,
myosin, and tropomyosin were increased 10.2- to 117-fold.
Thirdly, interleukin-1 (IL-1) related genes such as IL-1alpha,
beta, and IL-1 receptor were up-regulated by 12–15-fold. Cystatin
E/M and carboxylesterase 3 were most prone to down-regulation
by PDGF. The gene expression changes of chemokine and IL-1
family were confirmed by quantitative real-time PCR (Fig. 5, S1).
Quantitative Real-time PCR confirmation of PDGF-BB
induction
Since most gene expression changes were found in chemokine
family genes from the cDNArray profile, quantitative real-time
PCR was used to investigate these genes in more detail. As shown in
Fig. 5, CXCL 1 gene expression was higher in groups containing
25 mg PDGF encapsulated in high and low MW PLGA
microspheres than in other groups, while higher CXCL2 gene
expression was found only in the group containing 25 mgP D G F
encapsulated in high MW PLGA microspheres, compared to all
other groups. In addition, CXCL5 gene expression in the groups
containing 25 mg PDGF encapsulated in PLGA microspheres was
higher than that of the scaffold alone group and the two PDGF
coating groups, while the group containing 25 mg PDGF encapsu-
lated in HMW PLGA microspheres also had more CXCL5 gene
expression, compared to 2.5 mg PDGF encapsulated in the LMW
PLGA microspheres group. With regard to the CCL21b gene,
25 mg PDGF encapsulated in HMW PLGA microspheres group
had stronger CCL21b transcription than the scaffold alone and
both PDGF coating groups. The CCL21b gene expression within
the group containing 25 mg PDGF encapsulated in LMW PLGA
microspheres was higher compared to the scaffold alone group, the
two PDGF coating groups, and the 2.5 mg PDGF encapsulated in
LMW PLGA microspheres group. There was no statistically
significant difference between HMW and LMW microspheres
groups containing either 25 mg PDGF or 2.5 mg PDGF.
Discussion
PDGF is a multiple biofunctional growth factor, which partic-
ipates in cell migration, proliferation, chemotaxis, and vasculariza-
tion.[6,10,14]ThecurrentstudyshowsforthefirsttimethataPLLA
NFS/PLGA MS construct is favorable for PDGF delivery in vivo and
Figure 3. Nanofibrous scaffolds with PDGF microspheres promote vasculogenesis in vivo. Left panel is low magnification (106), right
panel is high magnification (406). Positive Factor VIII stained blood vessels were located in the central regions of the pores within penetrated tissues.
The blood vessels also permeated through the inter-openings between each pore. The group with 25 mg PDGF encapsulated in slow release PLGA
microspheres had measurably more vascularization.
doi:10.1371/journal.pone.0001729.g003
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vivo PDGF functions have a close relationship with chemokine family
members CXCL1, 2, 5, and CCL 21b and 22. Among them,
CXCL1 has been shown to be a PDGF-induced early gene.[25]
Biological delivery systems for proteins and peptides can mainly
be divided into two strategies: biomaterial delivery systems and gene
delivery systems. For the biomaterial delivery system, there are two
preparation methods: surface coating and encapsulation. In surface
coating preparation, the release rate of proteins and peptides is
primarily determined by the physico-chemical interactions between
protein and biomaterial. In contrast, the release rate of proteins and
peptides in encapsulation preparation occurs primarily via diffusion,
polymer degradation, or a combination thereof [26]. It has been
shown that release from low MW PLGA microspheres is diffusion
controlled, whereas release from high MW PLGA microspheres
typically occurs via a combination of diffusion and degradation. [27]
Due to easier control for molecular weight than the surface
interactions, delivery system by microspheres displays significant
advantages. The gene delivery system is referred to the delivery by
recombinant vectors such as recombinant plasmid, adenovirus,
retrovirus and adeno-associated virus, which carry the genes
encoding target proteins and peptides.
Our group has previously shown that in vitro release rate of
PDGF encapsulated in PLGA microspheres can be controlled by
PLGA MW. [23] HMW PLGA microspheres containing PDGF
take a longer time to be degraded and consequently release PDGF
more slowly, and vice versa. [23] In the present study, PLGA MW
shows an obvious relationship to the in vivo effects of PDGF
encapsulated by PLGA on tissue neogenesis and vascularization.
The groups with PDGF encapsulated in PLGA microspheres had
100% tissue penetration, while the groups with PDGF coated on the
surface of PLLA NFS resulted in only 20%–75% tissue penetration.
Furthermore, specimen areas in the groups with 25 mgP D G F
encapsulated in low and HMW PLGA microspheres and 2.5 mg
PDGF encapsulated in HMW PLGA microspheres were much
larger than other groups. These results indicate that tissue
penetration and specimen area are dependent on in vivo PDGF
release rate. In addition, the results of blood vessel number and area
also showed a similar relationship with in vivo PDGF release.
We also explored the effects of delivery systems on in vivo PDGF
function at the molecular level. The family of chemokines is
composed of small molecular weight peptides with highly conserved
cysteine motifs. Members of the chemokine family are categorized
into four groups depending on the spacing of their first two cysteine
residues. Their gene expression can be stimulated by many factors,
including growth factors such as PDGF [25] and proinflammatory
cytokines such as TNFa and IL-1.[28] These growth factor- and
cytokine-initiated chemokine gene expression effects occur primarily
through a phosphatidylinositol 3 kinase(PI3k)-Akt–Ikk-NF-kBp a t h -
way. [29,30] After NF-kBi sa c t i v a t e d ,N F - kB moves to the cell
nucleus and controls the expression of numerous genes related to
inflammation, tumor development, immune responses and tissue
repair. [31,32] Furthermore, Wood et. al. showed that the human
CXCL1 gene has an NF-kB binding site (GGGAATTTCC) in its
upstream promoter region, which is essential for IL-1 to induce
CXCL1 promoter activity. [33] Therefore, the effects of PDGF on
stimulating chemokine expression may depend on NF-kB.
A major role of chemokines is to guide the migration of cells but
they also have roles in development, promoting angiogenesis and
tracking cells to tissues that provide specific signals critical for
cellular maturation. Certain inflammatory chemokines activate
cells to initiate an immune response or promote wound healing
[34]. CXC chemokines have two N-terminal cysteines, separated
by one amino acid. CXC chemokines are subdivided into two
groups, those with a specific amino acid motif of Glutamate-
Leucine-Arginine (ELR) immediately before the first cysteine of
the CXC motif (ELR-positive), and those without an ELR motif
(ELR-negative). ELR-positive CXC chemokines specifically in-
duce the migration of neutrophils, and interact with chemokine
receptors CXCR1 and CXCR2. [35] These processes appear to
be important in linking PDGF’s effects during the inflammatory
cascade associated with subsequent tissue neogenesis.
In our study, PDGF induced chemokine gene expression in both
dose-dependent and duration-dependent manners. The CXCL1
gene expression induced by 25 mg PDGF encapsulated in low MW
and high MW PLGA microspheres was higher than that in the
scaffold alone group, PDGF coating group, and low dose PDGF
microsphere group.Incontrast, CXCL1 gene expression inducedby
2.5 mg PDGF encapsulated in low MW and high MW PLGA
microspheres had no significant differences from either the NFS
alone or PDGF coating groups, which indicates up-regulation of
CXCL1 gene expression stimulated by PDGF is dependent on
PDGF dose. This relationship is also seen in chemokines CXCL2,
CXCL5, and CCL21b.However,the geneexpression of CXCL1,2,
5, and CCL21b induced by 25 mgP D G Fc o a t e do nP L L As c a f f o l d s
(notencapsulatedinPLGAmicrospheres)wasnotdifferentfromthat
by the empty scaffolds or 2.5 mg (low dose) PDGF microsphere
groups, which suggests that PDGF release from PDGF-coated
scaffolds may be too rapid to be effective. Thus, the controlled
delivery of PDGF will likely be critical for clinical success.[36]
Although PDGF induced expression of CXCL1, 2, and 5, the
effects of these chemokines on PDGF function in vivo are still
unclear. These chemokines seem not to influence PDGF functions
on cell migration and proliferation because Nirodi et. al. reported
[37] that there was no CXC receptor II (CXCR2) for CXCL1, 2
and 5 in normal human skin, while CXCR2 was found to be rich
Figure 4. PDGF-containing microspheres in nanofibrous scaf-
folds increases angiogenesis in vivo. The blood vessel number was
measured within each group using sections immunostained with Factor
VIII antibody. Blood vessel number within both PDGF encapsulated, slow
release groups was significantly greater that that in other groups. The
bloodvesselnumberofPDGF-encapsulatedinthefastreleasePLGAgroup
showed no difference from that in the NFS-only group. * indicates p,0.01
doi:10.1371/journal.pone.0001729.g004
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kines in the current study play a role in angiogenesis. In addition,
CXCR2 is demonstrated to be the receptor responsible for ELR(+)
CXC chemokine-mediated angiogenesis.[38] ELR motif: (gluta-
mate-leucine-arginine motif) PDGF and CXC chemokines may
have synergistic effects on angiogenesis, because the PDGF effects
focus on pericytes and vascular smooth muscle cells and improve
blood vessel growth, while ELR(+) CXC chemokine primarily
affects endothelial cells. [38,39]
In summary, a sustained release delivery system is key for in vivo
PDGF application to promote tissue repair. In vivo,P D G Ff u n c t i o n s
in a dose-dependent and release mode-dependent manner. A
sustained release of PDGF not only influences tissue neogenesis
and neovascularization, but also impacts the PDGF-induced gene
profile of chemokine family members, actin, and interleukins. In
addition, the chemokine family may be an important downstream
factor for PDGF function. The use of controlled release NFS
incorporating PDGF-BB encapsulated microspheres offers signifi-
cant potential for soft and hard tissue engineering applications.
Supporting Information
Figure S1 Interleukin 1 (IL-1) and CCL22 gene expressions
induced with PDGF encapsulated microspheres in vivo. A: IL-1a
gene expression, B: IL-1b gene expression, C: IL-1 receptor type II
gene expression, D: CCL22 gene expression. * indicates p,0.01,
** indicates p,0.05.
Found at: doi:10.1371/journal.pone.0001729.s001 (9.30 MB TIF)
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Table 2. Gene expression profile of PDGF-BB encapsulated
microspheres in NFS vs. vehicle encapsulated microspheres in
NFS. List of genes with greater than 10-fold change in
expression from cDNArray analysis used as screening for
subsequent qPCR analysis.
Gene Fold Change
chemokine (C-X-C motif) ligand 1 148.95
actin, alpha 1, skeletal muscle 117.12
myosin, light polypeptide 2 86.93
similar to stefin A2 (predicted) 83.67
chemokine (C-X-C motif) ligand 5 66.65
chemokine (C-X-C motif) ligand 2 63.04
chemokine (C-C motif) ligand 21b (serine) 48.4
matrix metallopeptidase 3 47.66
Tryptophan hydroxylase 1 35.83
Transcribed locus 29.88
S100 calcium binding protein A9 (calgranulin B) 28.19
S100 calcium binding protein A8 (calgranulin A) 26.65
colony stimulating factor 3 (granulocyte) 26.22
gene model 1960, (NCBI) 25.67
similar to RIKEN cDNA 4933425K02 (predicted) 25.21
1388204_at 24.11
similar to MGC15476 protein (predicted) 23.44
sortilin-related receptor, L(DLR class) A repeats-containing
(predicted)
21.17
Tropomyosin 1, alpha 21.12
EGF-like-domain, multiple 6 20.42
carbonic anhydrase 4 19.61
Transcribed locus, moderately similar to XP_574280.1
PREDICTED: similar to Ab2-143
19.08
Transcribed locus, moderately similar to XP_574280.1
PREDICTED: similar to Ab2-143
19.06
fast myosin alkali light chain 18.88
gene model 1960, (NCBI) 18.66
inhibin beta-A 17.59
interleukin 1 beta 15.24
neurotrophin receptor associated death domain 15.07
myoglobin 14.64
interleukin 1 receptor, type II 13.96
Transcribed locus 13.59
gene model 1960, (NCBI) 13.24
Transcribed locus 13.07
interleukin 1 alpha 12.83
Transcribed locus 11.94
ephrin A1 11.81
Transcribed locus 11.25
cAMP responsive element modulator 10.57
procollagen, type XI, alpha 1 10.57
1392736_at 10.55
breast cancer anti-estrogen resistance 1 10.38
galanin 10.2
myosin, heavy polypeptide 4, skeletal muscle 10.17
prokineticin 2 10.13
Gene Fold Change
1385589_at 10.08
Down-
regulated
cystatin E/M 250.08
carboxylesterase 3 229.99
1375077_at 220.03
elastase 1, pancreatic 218.79
Similar to PIRB1 (predicted) 217.71
CD5 antigen-like 217.63
chemokine (C-C motif) ligand 22 215.63
secretin receptor 214.91
Similar to Ifi204 protein (predicted) 210.96
thyroid hormone responsive protein 210.77
Specimens harvested 7 days following treatment comparing the 25 mg PDGF-
encapsulated in slow release PLGA microsphere group as compared to scaffold-
only group are shown below.
doi:10.1371/journal.pone.0001729.t002
Table 2. cont.
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